Cowen upgrades Barr Pharmaceuticals (BRL) to Outperform
More News related to BRL
- Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
- Teva and Barr Receive FTC Request for Additional Information
- Teva and Barr Receive FTC Request for Additional Information
- Mylan (MYL) Subsidiary Announces Favorable Court Ruling Against Barr Labs (BRL)
- Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
More News related to Upgrades
- Merrill Lynch Downgrades Abercrombie & Fitch (ANF) to Underperform
- Deutsche Bank Lowers Rating On UST Inc (UST) From Buy To Hold
- Lazard Downgrades Navios Maritime (NM) to Hold
- B. Riley Downgrades Captaris (CAPA) to Neutral
- Lazard Downgrades Genco Shipping (GNK) to Hold
Cowen upgrades Barr Pharmaceuticals Inc. (NYSE: BRL) from Neutral to Outperform.
Barr Pharmaceuticals, Inc. engages in the development, manufacture, and marketing of generic and proprietary pharmaceuticals.
Related Categories
UpgradesStocks Mentioned
-0.08Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
